drugset / Trial / NCT05680480
A Study of Telitacicept in Lupus Nephritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Telitacicept in adult patients with active lupus nephritis.
Timeline
- Start
- 2023-04-17
- Primary completion
- 2025-12
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 240 mg | Subcutaneous |